| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 407.22 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Sickle Cell Disease (SCD) is a hereditary disease, and a worldwide public health problem, with a higher incidence in sub-Saharan Africa, where the prevalence is very high (about 80%). SCD prevalence can reach 3,3 % in Angola, while carriers of the sickle cell trait account for more than 25% of the population. The early identification of patients and their follow-up in consultation are an added value for the reduction of morbidity and mortality of children with SCD. The implementation of early infant screening and follow-up programs for children with SCD showed excellent results in increasing the survival of these children. With this project we intend to implement a Newborn screening in Hospital Materno Infantil Dr Manuel Pedro Azancot de Menezes, a referral of the main maternity in Angola, located in Luanda, the country capital, that could be replicated in other hospitals, giving training to the health professionals, and to the laboratory technicians, to diagnose the SCD patients. The objective of this project is to establish a neonatal screening for SCD at a main Hospital in Angola, contributing to reducing under-5 mortality and supporting pediatric follow-up consultations of children diagnosed with SCD. Specific aims include: recording the data and medical history of babies diagnosed with SCD up to 5 years of age at regular appointments; estimating the prevalence of SCD in the municipality of Camama, Luanda; and evaluating the costs of neonatal screening and early interventions in Angola, by supporting a registry of SCD.
Description
Keywords
Sickle cell disease Children Pediatric hospital Angola
Citation
Brito M, Inusa BP, Ginete C, Mendes M, Afonso R, Valentim I, et al. Implementation of a newborn screening for sickle cell disease, at the Hospital Materno Infantil Dr Manuel Pedro Azancot de Menezes, Angola. In: 65th ASH – American Society of Hematology Annual Meeting and Exposition 2023, San Diego (USA), December 9-12, 2023. Blood. 2023;142 Suppl 1:5300.